Guardant Health (NASDAQ:GH) Upgraded at Guggenheim

Guggenheim upgraded shares of Guardant Health (NASDAQ:GH) from a neutral rating to a buy rating in a report issued on Friday morning, MarketBeat Ratings reports. Guggenheim currently has $36.00 price objective on the stock.

A number of other research firms have also issued reports on GH. The Goldman Sachs Group dropped their price objective on shares of Guardant Health from $32.00 to $28.00 and set a buy rating on the stock in a research note on Monday, April 15th. Jefferies Financial Group started coverage on shares of Guardant Health in a research note on Monday, June 3rd. They issued a buy rating and a $32.00 price target for the company. Craig Hallum started coverage on shares of Guardant Health in a research note on Wednesday, April 24th. They issued a buy rating and a $28.00 price target for the company. Stephens restated an overweight rating and issued a $44.00 price target on shares of Guardant Health in a research note on Friday, May 24th. Finally, Canaccord Genuity Group lifted their price target on shares of Guardant Health from $30.00 to $38.00 and gave the stock a buy rating in a research note on Tuesday, June 4th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $36.83.

Guardant Health Stock Performance

Shares of GH opened at $28.88 on Friday. The company has a 50-day simple moving average of $24.98 and a 200-day simple moving average of $22.94. The company has a quick ratio of 5.66, a current ratio of 5.95 and a debt-to-equity ratio of 16.70. The company has a market capitalization of $3.53 billion, a PE ratio of -7.37 and a beta of 1.15. Guardant Health has a 52-week low of $15.81 and a 52-week high of $41.06.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, meeting the consensus estimate of ($0.94). Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. The firm had revenue of $168.49 million during the quarter, compared to the consensus estimate of $150.51 million. Equities research analysts predict that Guardant Health will post -3.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Guardant Health

Several hedge funds have recently added to or reduced their stakes in GH. Manchester Capital Management LLC acquired a new stake in Guardant Health in the 1st quarter valued at approximately $57,000. Headlands Technologies LLC grew its stake in Guardant Health by 362.3% in the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock valued at $64,000 after purchasing an additional 1,844 shares in the last quarter. Van ECK Associates Corp grew its stake in Guardant Health by 29.4% in the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after purchasing an additional 614 shares in the last quarter. EntryPoint Capital LLC bought a new position in Guardant Health in the first quarter valued at approximately $75,000. Finally, AXQ Capital LP bought a new position in Guardant Health in the third quarter valued at approximately $202,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.